We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00229424
First Posted: September 29, 2005
Last Update Posted: July 7, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
UCB Pharma
Information provided by:
Taiho Pharmaceutical Co., Ltd.
September 28, 2005
September 29, 2005
July 7, 2011
April 2005
October 2006   (Final data collection date for primary outcome measure)
Endoscopic healing rate [ Time Frame: At the eighth week after treatment ]
Endoscopic healing rate
Complete list of historical versions of study NCT00229424 on ClinicalTrials.gov Archive Site
Frequency of heartburn symptom, intensity and improvement effect in other subjective symptoms and dosing frequency of MALFA ® suspension (neutralizer) [ Time Frame: Everyday ]
Frequency of heartburn symptom, intensity and improvement effect in other subjective symptoms and dosing frequency of MALFA ® suspension (neutralizer)
Not Provided
Not Provided
 
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the patients with mild reflux oesophagitis.

Furthermore, the followings are compared:

The improvement effect in heartburn and other subjective symptoms, and dosing frequency of MALFA ® suspension (neutralizer) as well as incidence of adverse events among the lafutidine 20 mg/day treatment group, the famotidine 40 mg/day treatment group and the placebo treatment group in patients with mild reflux oesophagitis.

In Japan it is reported that many patients with reflux oesophagitis are relatively mild and do not usually require strong treatment, and even H2 receptor antagonists are considered to demonstrate sufficient healing effects. Haruma thinks that the first choice should be PPI in principle which has the best therapeutic effect as the medical guideline if a patient has a strong reflux symptom such as heartburn or is diagnosed with severe reflux oesophagitis (Grade C or D according to the Los Angels Classification) as a result of the upper gastrointestinal endoscopic test. Later, after healing is confirmed at 8 weeks of treatment or after the subjective symptoms have been improved, the dose of PPI should be reduced to half to transfer to maintenance therapy. On the other hand, if a patient has mild subjective symptoms or develops mild reflux oesophagitis (Grade A or B according to the Los Angels Classification) as a result of the upper gastrointestinal endoscopic test, only about 10% of such patients aggravate in the long-run and some patients heal in the natural course. Therefore, considering that Japanese gastric-acid secretion is lower than Westerners, they recommend that antacids such as H2 receptor antagonists or sodium alginates is used to treat symptoms as they appear along with the improvement in the lifestyle. As mentioned above, lafutidine that strongly suppresses acid secretion during the daytime from the initial phase of treatment is expected to demonstrate sufficient effect in treatment of mild reflux oesophagitis similar to the conventional H2 receptor antagonists.

Based on above, the clinical trial is planned with the objective to confirmedly demonstrate the efficacy of lafutidine in mild reflux oesophagitis.

Comparisons: The endoscopic healing rate of lafutidine in the patients with mild reflux oesophagitis is compared to the rate of placebo and it is also compared to the rate of famotidine.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Gastroesophageal Reflux
  • Drug: Lafutidine
    Oral administration of lafutidine by 20mg/day along with famotidine placebo
  • Drug: Famotidine
    Oral administration of famotidine by 40mg/day along with lafutidine placebo
  • Other: Placebo
    Oral administration of lafutidine placebo along with famotidine placebo
  • Experimental: 1
    Lafutidine group
    Intervention: Drug: Lafutidine
  • Active Comparator: 2
    Famotidine group
    Intervention: Drug: Famotidine
  • Placebo Comparator: 3
    Placebo group
    Intervention: Other: Placebo
Ohara S, Haruma K, Kinoshita Y, Kusano M. [Efficacy evaluation of lafutidine for mild reflux esophagitis in Japanese patients]. Nihon Shokakibyo Gakkai Zasshi. 2010 Apr;107(4):588-97. Japanese.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
325
January 2007
October 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 20 and over (at the time of consent given)
  • Gender and inpatient or outpatient: Irrelevant
  • Patients diagnosed with Grade A or Grade B mild reflux oesophagitis (according to the Los Angels classification) through endoscopic test
  • Patients who complained about "heartburn symptom" within one week prior to the enrollment

Exclusion Criteria:

  • Patients whose "heartburn symptom" has been disappeared (not been observed at all) during the observation period (Check before official enrollment)
  • Patients in ill compliance with dosing the investigational product for the observation period (Not more than 75%, check from the patient dairy before official enrollment)
  • Patients the investigator/sub-investigator assessed difficult to complete the patient diary during the treatment period because the patient diary for the observation period has too many deficiencies. (Check before official enrollment)
  • Patients with complication of gastric/duodenal ulcer (scarring acceptable)
  • Patients with complication of Barrett lining over the site exceeding 3 cm of esophageal distal portion
  • Patients who have received the normal dose of H2 receptor antagonist or proton pump inhibitor (PPI) for 8 weeks in vain
  • Patients whose Helicobacter pylori was successfully eradicated within 24 weeks
  • Patients with medical history of upper gastrointestinal tract excision
  • Patients with complication of angina pectoris
  • Patients who have received treatment of any other investigational product within 12 weeks
  • Patients who showed any of the following values at the laboratory tests before official enrollment: Hemoglobin: < 9.5 g/dL, WBC: < 3,000/mm^3, Thrombocytes: < 75,000/mm^3, AST and ALT : ≥ 100 IU/L, Creatinine: ≥ 1.5 mg/dL These should be assessed using the current test values from the blood drawn within 4 weeks prior to official enrollment.
  • Patients with complication of serious cardiac disorder (Grade 3 or above under PAB/SD Notification No. 80) For example, patients with triplet or more ventricular premature contractions (multi-sources) or using a pacemaker
  • Patients with medical history of serious hypersensitivity to drugs (Grade 3 or above under PAB/SD Notification No. 80)
  • Patients who receive treatment of cancer
  • Women of confirmed or potential pregnancy, those who wish to become pregnant, and breast feeding women
  • Patients having any other condition that, in the opinion of the investigator/sub-investigator disqualifies them for the trial
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT00229424
10019350
LAF/GER/3D1/FN/01
Not Provided
Not Provided
Not Provided
Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
UCB Pharma
Principal Investigator: Tomoyuki Koike, MD Tohoku University Hospital
Taiho Pharmaceutical Co., Ltd.
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP